Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22472935 | 0.87 | HPGD (0.47) | ALDH1A1TSHRPOLBHPGDKMT2A | |
| SCHEMBL21597933 | 0.84 | ALDH1A1 (0.50) | ALDH1A1TSHRCHRM1MAPTPOLB | |
| SCHEMBL22472926 | 0.76 | MAPK1 (0.43) | ALDH1A1CHRM1KMT2AMEN1MAPK1 | |
| SCHEMBL22472885 | 0.76 | CHRM1 (0.47) | ALDH1A1CHRM1MAPTL3MBTL1SMN1; SMN2 | |
| SCHEMBL22472884 | 0.76 | CHRM1 (0.46) | ALDH1A1CHRM1KMT2AMEN1LMNA | |
| SCHEMBL22472944 | 0.75 | CHRM1 (0.67) | ALDH1A1CHRM1SMN1; SMN2 | |
| SCHEMBL22472890 | 0.75 | MAPK1 (0.41) | CHRM1KMT2AMEN1MAPK1 | |
| SCHEMBL22472873 | 0.73 | CHRM1 (0.39) | CHRM1MAPTPOLBKMT2AMEN1 | |
| SCHEMBL22472933 | 0.72 | HPGD (0.44) | ALDH1A1TSHRCHRM1POLBHPGD | |
| SCHEMBL14978882 | 0.71 | CHRM1 (0.57) | ALDH1A1TSHRCHRM1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787447-B2 | Pharmaceutical compounds | HEPTARES THERAPEUTICS LIMITED (GB) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787447-B2 | Pharmaceutical compounds | CHRM1, CHRM2, CHRM4 | ALDH1A1 2016/4885TSHR 79/4885CHRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.